Business Context and Reporting Period
This Form 8-K is a current report filed by Fluidigm Corporation (not Standard BioTools Inc.) on November 8, 2021. The filing serves to announce the company's financial results for the third fiscal quarter of 2021. The registrant is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol FLDM.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the third fiscal quarter of 2021 were reported.
Guidance, Outlook, and Risks
The document does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information furnished, including the attached press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into future filings except as expressly set forth.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release), as they are absent from this 8-K summary text.
- Confirm the distinction between the registrant name in the metadata (Standard BioTools Inc.) and the actual filing entity (Fluidigm Corporation), noting that Standard BioTools acquired Fluidigm in a subsequent transaction.
- Review the full press release for any forward-looking statements or guidance that may have been issued alongside the Q3 2021 results.